Epsilon M&A Deal Report - Azur Genetique
Transaction Multiples for the Valuation of Private Companies
Laboratoires B2A / Azur Genetique
No EMAT :
113543
Announced Date :
18/03/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Laboratoires B2A
Target :
Azur Genetique
Country :
Alpes-Maritimes
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Azur Genetics is a genetic identification laboratory , specialized in the field of human genetic fingerprints for more than twelve years. > Its activity is primarily devoted to judicial requisitions...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
|
|
|
|
| Current |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 51
| Date | Acquirer | Target | Country | Multiples | See details |
| 31/07/2023 | Mindray Medical Netherlands | DiaSys Diagnostic Systems | Germany | * | 113498 |
| 20/07/2021 | Damartex | MSanté, Optimum Medical, Perf-R, JP Consult, Groupe Médical Santé | France | ** | 113120 |
Source: Epsilon Research / EMAT
